Finanznachrichten24d
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
Topical LUT014 Treats EGFRi (Epidermal Growth Factor Receptor Inhibitor) Induced Acneiform Rash, Potentially Improving The Treatment's Efficacy And Patients' Quality of Life TEL AVIV, Israel ...
PR Newswire24d
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
Topical LUT014 Treats EGFRi (Epidermal Growth Factor Receptor Inhibitor) Induced Acneiform Rash, Potentially Improving The Treatment's Efficacy And Patients' Quality of Life While EGFRi therapies ...
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
Morningstar9d
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
The most frequent rashes included dermatitis acneiform, rash, eczema, maculo-papular rash and pustular rash. In the pooled adult safety population, rash occurred in 92% of patients treated with ...
Targeted Oncology1d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Glamour25d
Scalp Acne: How to Prevent and Treat Breakouts on Your Head
Board-certified dermatologist Ellen Marmur, MD, says that in 99% of cases, breakouts are actually acneiform scalp rashes: small bumps that resemble acne and are technically considered folliculitis.